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1 Introduction and background 
Rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are the 
three most prevalent chronic inflammatory arthropathies. Cardiac involvement such as valve 
disorders, peri-/myocarditis and conduction defects have been recognized for several years, 
particularly in AS and RA. However, in recent years, several studies have indicated that 
inflammatory arthropathies also are associated with an excess risk of cardiovascular disease 
(CVD) such as coronary heart disease caused by atherosclerosis. Atherosclerosis, which is 
fatty deposits in the artery walls, leads to structural changes of the vessels, and is often 
preceded or coincidental with functional changes of the arteries. During the last decades, 
atherosclerosis has emerged as an inflammatory disease (1), and the inflammatory processes 
in atherosclerosis and inflammatory arthropathies share several features (2). Drugs targeting 
the pro-inflammatory cytokine Tumor Necrosis Factor-α (TNF-α) have since their 
introduction in the late 90’s revolutionized the treatment of inflammatory arthropathies. 
Against this background, the aim of this thesis was to explore whether anti-TNF-α therapy 
could be beneficial with regard to vascular pathology in inflammatory arthropathies. In 2005 
when this thesis was initiated, knowledge about vascular effects of anti-TNF-α therapy was 
limited; it will be described in the Introduction and background part of this dissertation. Since 
then, the research activity within this field has increased considerably, and the results from the 
studies in this thesis will be discussed in light of more recent publications in the General 
discussion part. 
1.1 Inflammatory arthropathies 
The prevalence of RA is about 0.5-1.0 % in Caucasians, but varies across populations (3). 
Women are affected two to five times more often than men. RA can occur in patients at any 
age, but the highest incident rates are at the ages between 60 and 70 (4). The disease is 
characterized by synovial inflammation that commonly affects small joints of the hands and 
feet symmetrically, but also frequently involve larger joints like the shoulder and knee. While 
the etiology of RA is largely unknown, it is often associated with anti-cyclic citrullinated 
peptide (anti-CCP) antibodies. Both genetic and environmental factor have been recognized to 
increase the risk of developing anti-CCP antibodies (5). Although disease activity may vary 
over time, RA is considered a progressive disease. If the disease is uncontrolled, it may lead 
to destruction of joints due to cartilage degradation and bone erosion.  
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AS and PsA belong to a group of interrelated inflammatory arthropathies which collectively 
are called spondyloarthropathies (6), or more recently spondyloarthritis (7). 
Spondylarthropathies are not associated with anti-CCP antibodies, but show relationship with 
positivity of human leukocyte antigen-B27 (8). AS typically affects the sacroiliac joints, the 
axial skeleton and entheses, and is characterized by progressive spinal ankylosis due to new 
bone formation. AS is frequently associated with iridocyclitis, uveitis and inflammatory 
bowel disease. The disease characteristically affects young adults with a peak age of onset 
between 20 and 30 years. The prevalence of AS is lower than of RA, and AS is two to three 
times more frequent in men than in women. PsA affects women and men equally, with a 
prevalence of about 0.1 to 0.2 % (9). Disease onset is most frequent in the fifth decade of life. 
PsA is associated with psoriasis and typically affects peripheral joints such as the distal 
interphalangeal joints, but may also involve the spine. PsA commonly presents as an 
asymmetrical oligoarthritis or as a polyarthritis, although the pattern of arthritis may change 
over time. PsA with peripheral joint involvement is an erosive disease leading to resorption of 
cortical bone but is also associated with calcification and ossification at the sites of entheses 
(10). 
1.2 Cardiovascular risk in RA 
A considerable body of evidence supports the fact that RA is associated with an increased risk 
of cardiovascular mortality and morbidity compared to the general population. Van Doornum 
et al reviewed the results published prior to and including 2000 and showed that patients with 
RA had a reduced life expectancy by 3-18 years and a standardized mortality ratio of 1.7 (11). 
The excess mortality was mainly due to increased levels of cardiovascular death. Later, 
several other studies have reported similar findings (12-18).  
Endothelial dysfunction (chapter 1.4.1) and arterial stiffening (chapter 3.2.1) are markers of 
vascular dysfunction and independent predictors of CVD in the general population (19;20). 
Compatible with the observed excess cardiovascular risk, also unfavorable changes in these 
vascular parameters have been demonstrated in patients with RA compared to control 
populations (21-27). Indicators of premature atherosclerosis such as increased levels of 
carotid intima media thickness (CIMT [chapter 3.2.2]) and carotid plaques have also been 
associated with RA (28-33).  
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Some cardiovascular risk factors, in particular smoking, dyslipidemia (increased atherogenic 
index; total cholesterol / high density lipoprotein cholesterol and increased levels of small 
dense low density lipoprotein cholesterol [LDL] particles) and insulin resistance, seem to be 
more frequent in patients with RA than in the general population (11;34;35). Furthermore, 
reduced physical activity due to the joint disease and fatigue might negatively influence the 
cardiovascular risk. Thus, an unfavourable cardiovascular risk profile might contribute to the 
accelerated atherosclerosis in RA. Nevertheless, the excess risk is only minimally attenuated 
by traditional risk factor adjustment (12;36), and also compared with patients with 
osteoarthritis, RA patients remain at higher cardiovascular risk (15;37). Several of the 
manifestations of RA such as higher deformed joint count, longer disease duration and higher 
disease activity have been associated with increased cardiovascular risk in different studies 
(11;14;36). These results indicate that the level of inflammation in patients with RA 
accelerates the atherosclerotic process, possibly through both an unfavourable influence on 
traditional risk factors and direct effects on the artery wall (11;34). In line with this 
interpretation, previous cross sectional studies have indicated that inflammatory markers 
correlate with vascular pathology both in patients with RA and in the general population 
(21;23;26;32;38-40).   
1.3 Cardiovascular risk in AS and PsA  
Patients with AS have already in the late 70’s been reported to have increased all-cause 
mortality and augmented risk of cardiovascular death (41), and later similar findings have 
been reported in patients with PsA (42). However, available results on cardiac morbidity and 
mortality in these patients are limited and precise information about the specific type of 
cardiac disease has not been reported (41;43;44). In AS, cardiac involvement such as aortic 
root disease and valve disease have been associated with cardiovascular morbidity (45), and 
thus the cardiovascular risk due to atherosclerotic processes in these patients may be difficult 
to estimate. Nevertheless, Peters et al, in their review from 2004, concluded that available 
data all-together point to an increased risk of atherosclerotic CVD also in patients with AS 
and PsA (46). In concordance with this conclusion, Divecha et al have reported that patients 
with AS have increased levels of cardiovascular risk factors such as increased pulse pressure, 
fibrinogen levels and von Willebrand factor compared to controls (47). Furthermore, in the 
study by Divecha et al, systemic inflammation seemed to be associated with an unbeneficial 
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cardiovascular risk profile, which may indicate a role of systemic inflammation in premature 
atherosclerosis in AS similar to that in RA (47). 
Previous data regarding vascular function and CIMT in PsA are missing, and only one study 
has assessed this issue in patients with AS. In this study, patients with AS had impaired 
endothelial function compared to healthy controls, whereas the CIMT values were not 
different between the two groups (48). However, this study included young patients at an 
average age of 37 years. Normally, atherosclerotic changes appear with age. Thus, studies 
with older patients or larger patient groups may be necessary to determine a possible presence 
of premature atherosclerosis in patients with AS and PsA.   
1.4 Cardiovascular disease and inflammation 
An increasing body of evidence supports the involvement of inflammatory mechanisms in 
atherosclerosis and vascular pathology, not only in patients with inflammatory arthropathies, 
but also in the general population (49). Cohort studies have shown that high sensitivity C-
reactive protein (CRP) predicts incident myocardial infarction and cardiovascular death also 
after adjustment for traditional cardiovascular risk factors (50). In line with these results, 
inflammatory mediators are abundantly expressed during atherogenesis and are demonstrated 
to augment the atherosclerotic process (49). Patients with inflammatory arthropathies do not 
only express CRP in the high sensitivity range, but often have a high-grade systemic 
inflammation, which may accelerate the development of vascular pathology (34). 
1.4.1 Inflammation and vascular function  
The normal healthy endothelium is a major regulator of vascular homeostasis and modulates 
vascular tone and structure, smooth muscle cell proliferation and migration, coagulation, cell 
adhesiveness and vessel wall inflammation (49;51). Endothelial dysfunction, which refers to a 
disruption of the endothelium’s vasoprotective properties, is considered as an initial step in 
the atherosclerotic process. Nitric oxide (NO), which is produced by the endothelial cells, 
mediates many of the endothelium’s functions. One of the main characteristics of endothelial 
dysfunction is impaired endothelium dependent vasodilatation because of reduced NO 
bioavailability. Inflammatory processes have been demonstrated to suppress NO mediated 
vasodilatation partly through increased oxidative stress (52). Oxidative stress uncouples the 
enzyme nitric oxide synthase (NOS) which synthesizes NO from the amino acid L-arginine. 
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Another characteristic of endothelial dysfunction is endothelial activation. Activated 
endothelial cells express adhesion molecules such as vascular cell adhesion molecule-1, 
intercellular cell adhesion molecule-1 and e-selectin on their surface (49). Leucocytes are 
recruited to the artery intima by adhesion to the activated endothelium and migration through 
the endothelial layer. The migration process is facilitated by chemo attractant stimuli 
including chemokines (i.e monocyte chemoattractant protein-1) (53). Endothelial activation 
typically takes place at atherosclerosis prone sites such as arterial branching points and 
curvatures. Blood flow at these sites is characterized by turbulent flow and low average shear 
stress (tangential stress from the blood flow on the endothelium and the inner layers of the 
artery wall). Low shear stress has been demonstrated to promote expression of adhesion 
molecules, up-regulation of inflammatory genes and to reduce NO production in endothelial 
cells (54). Additionally, numerous stimuli including hypercholesterolemia and infiltration of 
LDL to the intima (55), hypertension, smoking and inflammatory mediators may induce 
endothelial activation (49).  
The main determinants of large artery stiffness are the structural elements within the arterial 
wall, vascular muscle tone and blood pressure (20;56). Inflammatory mediated endothelial 
dysfunction may consequently promote functional arterial stiffening by reducing vascular 
vasodilatory capacity. Furthermore, the inflammatory cells recruited to the artery wall may 
directly affect smooth muscle cells, or contribute to changes in the composition of the artery 
wall and thus promote structural arterial stiffening (57). Inflammatory mediators including 
TNF-α stimulate release of matrix metalloproteinases (MMPs) (58). MMPs are a family of 
enzymes with proteolytic activity against extracellular matrix components such as elastin, 
collagen and proteoglycans. MMPs play an important role in vascular remodeling, and 
contribute to vascular adaptation and repair. However, with excessive MMP activity, 
inappropriate vascular remodeling may occur, and it has been shown that circulating MMP-9 
levels are independently associated with aortic stiffness (59). Furthermore, inflammation may 
promote arterial stiffening through calcification of the artery wall. In vitro studies have 
demonstrated that monocyte- and macrophage derived TNF-α may induce alkaline 
phosphotase production, which is a marker of osteoblastic differentiation, and calcification in 
vascular smooth muscle cells (60;61). On the other hand, arterial stiffening may itself promote 
endothelial dysfunction by reducing shear stress and consequently endothelial NO production 
(62). Stiffer arteries may also directly advance atherosclerosis via increased pulse pressure 
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and changes in mechanical stress in the artery wall leading to damaged wall structure and thus 
increased susceptibility to atherosclerosis (20).  
Infiltration of leucocytes and LDL might lead to structural atherosclerotic changes in the 
artery wall (chapter 1.4.2). However, alterations in blood flow, blood pressure and shear stress 
may also induce compensatory and non-atherosclerotic arterial wall thickening (63). Shear 
stress and tensile stress (the stretching force perpendicular to a longitudinal section through 
the artery wall or tangential to the wall) are major determinants of adaptive remodeling of the 
arterial wall. Both shear stress and tensile stress are kept relatively constant throughout the 
artery, and changes in shear stress and subsequently in lumen diameter are followed by 
changes in artery wall thickness to keep tensile stress constant (64).  
1.4.2 Inflammation and atherosclerosis 
After recruited to the artery wall (chapter 1.4.1), the leucocytes undergoes differentiation and 
activation. Under the influence of macrophage colony stimulating factor produced by 
endothelial cells and smooth muscle cells, monocytes differentiate into macrophages (65). 
Macrophage differentiation involves increased expression of pattern recognition receptors 
such as scavenger receptors and toll-like receptors (TLRs). Scavenger receptors mediate the 
uptake of numerous molecules and particles including oxidized LDL (66). Excessive uptake 
of oxidized LDL leads to accumulation of cytosolic cholesterol droplets, which induce 
macrophage foam cell formation. Ligand binding to TLRs triggers signaling that leads to 
activation of the intra nuclear factor-κ beta (NF-κB). NF-κB induces expression of pro-
inflammatory cytokines that activate macrophages and other inflammatory cells. T-cells 
differentiate into T helper cells-1 and T helper cells -2 and regulatory T-cells after antigen 
presentation by macrophages or dendritic cells and co-stimulatory signaling. Previous results 
have indicated that T helper cells-1 dominates in atherosclerosis (67). T helper cells-1 
responses generally amplify the inflammatory cascade by secretion of cytokines including 
interferon-γ and TNF-α. Also other inflammatory cell such as mast cells populate 
atherosclerotic lesions (68).  
With time, lipoprotein infiltration and inflammation lead to development of atherosclerotic 
plaques. Atherosclerotic plaques contain inflammatory cells, as well as vascular endothelial 
cells, extracellular matrix, lipids and lipid-rich debris (69). In the centre of a plaque, 
macrophage foam cells and extracellular lipid droplets form a core region that is surrounded 
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by a cap of smooth muscle cells and a collagen rich matrix (69). The plaque can progress into 
an even more complex lesion in which the lipid core is surrounded by a fibrous cap. T-cells 
and macrophages infiltrate throughout the lesion and are particularly abundant in the shoulder 
region of the plaque and at the interface between the cap and the core. The inflammatory cells 
produce proteases, pro-inflammatory cytokines and protrombotic factors which destruct 
collagen and inhibit smooth muscle growth (70). The destabilized fibrous cap might fissure, 
usually at the shoulder region, and reveal thrombogenic plaque material. The exposed plaque 
material induces formation of a thrombus and consequently a clinical cardiovascular event.   
1.4.3 TNF-α  
TNF-α (also called TNF) is a pro-inflammatory cytokine which is produced predominantly by 
activated macrophages and Th1 cells (71). TNF-α is an early and important trigger for 
downstream mechanisms and acts within a complex network of cells and mediators of 
inflammation. TNF-α is initially expressed in the plasma membrane (transmembrane TNF-α) 
but can be released in a soluble form (soluble TNF-α) after enzymatic cleavage. Soluble TNF-
α and transmembrane TNF-α are both biologically active. TNF-α binds to TNF-α receptor-1 
and -2 (TNFR1 and TNFR2) (72). TNFR1 is constitutively expressed on virtually all 
nucleated cells, whereas TNFR2 is generally inducible and is preferably expressed on 
endothelial and hematopoietic cells (71). The effects of  soluble TNF-α and transmembrane 
TNF-α can be pro-inflammatory through activation of NF-κB, which leads to enhanced 
expression of pro-inflammatory cytokines, or lead to apoptosis, depending on the metabolic 
state of the cell (73). These pro-inflammatory and apoptotic pathways are mainly mediated 
through TNFR1. The consequences of TNFR2 signaling have been less well described but 
seem to promote cell proliferation, angiogenesis and NF-κB activation (72).  
TNF-α is usually not detectable in healthy individuals, but elevated serum and tissue levels 
are found in several inflammatory and infectious conditions (74;75). At low concentrations in 
tissues, TNF-α is thought to have beneficial effects, such as augmentation of host defense 
mechanisms against infections. At high concentrations, TNF-α can lead to a too excessive 
inflammatory response and consequently organ damage.  
TNF-α has during the last decades been demonstrated to have a pivotal role in RA pathology 
(76). Activated macrophages are an important source of TNF-α in inflamed synovial tissue, 
and both the number of macrophages and the degree of TNF-α expression have been shown to 
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correlate with clinical measures of RA activity (77). TNF-α produced by the cells in the 
inflamed tissues also have been demonstrated to influence osteoclast differentiation and may 
thus promote bone destruction (10). Furthermore, transgenic mice expressing high levels of 
human TNF-α have been demonstrated to develop an inflammatory arthritis that resembled 
RA and which could be prevented by administration of monoclonal antibodies to human TNF-
α (78). Finally, treatment with antibodies against TNF-α has been shown to significantly 
improve disease activity in patients with RA (79). TNF-α is also demonstrated to have a 
central role in AS and PsA. The cytokine has been detected in sacroiliac joints in patients with 
AS (80) and in synovial fluid in patients with PsA (81), and plasma levels correlate with the 
disease activity in AS patients (82). In line with the results from studies in patients with RA, 
TNF-α inhibition has been demonstrated improve disease activity also in patients with AS and 
PsA (83;84). 
Data also support a central role for TNF-α in atherosclerosis and heart failure. Increased 
circulating levels of the cytokine have been shown in patients with myocardial infarction and 
patients with heart failure and predict recurrent cardiovascular events (85;86). Inflammatory 
cytokines are produced in the failing heart and seem to contribute to cardiac dysfunction (87). 
In a study with apolipoprotein E deficient mice, which are prone to atherosclerosis, the mice 
also deficient in TNF-α developed significantly less atherosclerotic lesions than the single 
apolipoprotein E deficient mice (88).  During development of vascular pathology and 
atherosclerosis (chapter 1.4), TNF-α promotes the endothelial cell activation (89) and 
augments the inflammatory process in the artery wall. Further effects of TNF-α on vascular 
pathology might include impairment of NO bioavailability with consequent promotion of 
endothelial vasomotoric dysfunction (90). TNF-α is also demonstrated to promote thrombosis 
by increased expression of pro-coagulant proteins such as tissue factor. Furthermore, TNF-α 
also has profound metabolic effects, including promotion of insulin resistance and 
dyslipidemia (34).  
1.5 Anti-inflammatory pharmacotherapy and CVD  
A natural consequence of the central role of inflammation in atherogenesis and vascular 
pathology would be a beneficial effect on CVD from anti-inflammatory treatment. Studies 
have demonstrated that statin (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) 
treatment not only lowers lipid levels, but also CRP levels in both the general population and 
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in patients with RA (91;92). Additionally, lipid lowering treatment improved disease activity 
and arterial stiffness in patients with RA (91;93). However, specific anti-inflammatory 
treatment strategies have not yet been proven favorable with regard to cardiovascular outcome 
in the general population. Whether treatment that lowers disease activity in inflammatory 
arthropathies may influence CVD, has been debated. Although the anti-inflammatory effect 
might be beneficial, commonly used drugs have been reported to have pro-atherogenic side 
effects. Available data regarding the effect on CVD of anti-inflammatory therapy include 
studies in the general population and RA patients with glucocorticoids, methotrexate (MTX), 
non-steroidal anti-inflammatory drugs (NSAIDs), selective cyclooxygenase (COX)-2 
inhibitors and TNF-α antagonists.  
1.5.1 Glucocorticoids, MTX, NSAIDs, COX-2 inhibitors and CVD  
Treatment with glucocorticoids, which is common in both RA, AS, PsA and several other 
non-rheumatic conditions, has been associated with increased risk of CVD, particularly heart 
failure, in two large studies in the general population (94;95). The cardiovascular risk was 
largest in the patient group taking the highest oral dose of glucocorticoids, whereas a topical, 
nasal and inhaled use did not seem to increase the risk. These results were also valid in sub 
analyses which included only patients with inflammatory arthropathies. Studies addressing the 
effect of glucocorticoids on arterial wall properties in patients with RA seem to support these 
findings. Kumeda et al and Park et al have both reported that low dose (≤10 mg prednisolone) 
oral glucocorticoid use was not associated with increased CIMT values (31;33). These 
findings were later repeated by Del Rincon et al (96). Furthermore, in del Rincon et al’s 
cohort of RA patients, those in the highest tertile of lifetime glucocorticoid exposure (>16.24 
mg prednisone daily) had an increased frequency of carotid plaques and lower-limb arterial 
incompressibility (96). In line with these results, a review of the safety data from randomized 
controlled trials (RCTs) of low dose glucocorticoid treatment (≤10 mg prednisolone 
equivalent daily) in RA concluded that such treatment did not increase the risk of 
cardiovascular events (97). Furthermore, using low dose glucocorticoids did not significantly 
affect blood pressures. Thus, the overall body of evidence indicates that moderate and high 
doses, but not low doses, of glucocorticoids are unfavorable with regard to CVD both in the 
general population and in RA patients.  
MTX is an important drug in the treatment of RA, and is also used in PsA. Krause et al have 
demonstrated that patients who do not respond to MTX treatment have an increased all cause 
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mortality compared to both patients with response to the drug and the general population (98).  
In conflict with this result, Landewe et al have reported in a research letter the same year that 
RA patients with pre-existing cardiovascular disease who started MTX treatment had a higher 
risk of death during follow-up than other patients in their cohort (99). Treatment with MTX in 
patients without pre-existing CVD, however, was not associated with increased mortality. 
Later, Choi et al have shown that MTX use reduce all-cause mortality in 1240 patients with 
RA, and that the main reduction was because of a reduced cardiovascular mortality (100). 
This finding was later supported by another study, in which the risk of hospitalization for 
heart failure was reduced by treatment with MTX (101). With regard to the effect of MTX on 
vascular function and structure, previous results are limited. Two cross sectional studies have 
addressed this issue, and both have shown that current MTX use did not influence CIMT 
values (31;33). All together, existing results indicate a beneficial effect of MTX on CVD, 
although further studies are needed. 
Conventional NSAIDs and selective COX-2 inhibitors are extensively used in inflammatory 
arthropathies, and are the cornerstone in the therapy of AS. Concerns about cardiovascular 
adverse events associated with use of these medications arose in the early 2000’s. The 
VIGOR (Vioxx GI Outcomes Research) study, which compared upper gastrointestinal clinical 
events but also reported adverse cardiovascular events, of rofecoxib and naproxen in patients 
with RA, had indicated a significant 4-fold increased risk of acute myocardial infarction with 
rofecoxib compared to naproxen (102). An increased risk of acute myocardial infarction or 
thrombotic cardiovascular events with rofecoxib therapy was also noted in a 2004 meta-
analysis and in a trial of rofecoxib versus placebo for prevention of adenomatous colonic 
polyps, the APPROVe (Adenomatous Polyp PRevention On Vioxx) study (103;104). 
Rofecoxib was withdrawn from the marked in September 2004. The use of other non-
naproxen NSAIDs and selective COX-2 inhibitors also seem to be associated with an 
increased risk of cardiovascular events (105;106). However, the absolute risk is low, 
particularly when low doses are used and in patients with low cardiovascular risk. Naproxen 
appears to be the safest with respect to such risk, also in patients with RA (107;108). Studies 
assessing the effect of NSAIDs and selective COX-2 inhibitors on vascular function are 
limited.  
The majority of data on cardiovascular effects of anti-inflammatory treatment in patients with 
inflammatory arthropahties are from cohort and case-control studies. When interpreting these 
results, a general problem is that patients with higher disease activity, and probably larger 
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inflammatory burden, most likely would receive more active treatment. Thus, many of these 
studies are confounded by indication. Furthermore, patients often use combinations of 
different medications and some drugs only for short periods. It has also been speculated that 
some of the beneficial effects observed with TNF-α antagonist (chapter 1.5.2) and MTX 
might be a steroid saving effect. Thus, results from this kind of studies need to be adjusted for 
confounding factors and to be interpreted with caution.    
1.5.2 Anti-TNF-α therapy and CVD  
The TNF-α antagonists infliximab, etanercept and adalimumab, which were the TNF-α 
antagonists in regular use at the time of initiation of this thesis, are all effective therapeutic 
agents in the main inflammatory arthropathies, and have since their introduction dramatically 
improved the outcome in these diseases. Infliximab and adalimumab are monoclonal 
antibodies and etanercept is a TNF-α receptor Fc-fusion protein. Accordingly, the TNF-α 
antagonists have a somewhat different mode of action, but clinical studies indicate 
comparable efficacy of these drugs in RA (109). Although TNF-α antagonists first were 
introduced for the treatment of RA, their effectiveness with regard to health-related quality of 
life is at least as good in AS (110). Furthermore, anti-TNF-α therapy has been demonstrated 
to induce a rapid reduction in synovial inflammatory cells in both RA, AS and PsA (111-113). 
Due to the demonstrated role of TNF-α in heart failure and the positive experiences from anti-
TNF-α therapy trials in patients with RA (chapter 1.4.3), RCTs with etanercept and infliximab 
in patients with chronic heart failure were conducted in the beginning of the 2000’s (114;115). 
Pilot studies had shown improvement in left ventricular ejection fraction after initiation of 
etanercept (116;117), and a small study had demonstrated that etanercept improved 
endothelial dysfunction in patients with advanced heart failure (118). However, the RCTs of 
etanercept in heart failure showed no benefit of this drug, and treatment with infliximab in the 
highest dose (10 mg/kg) significantly increased heart failure hospitalization and death from 
any cause (114;115). It has later been speculated that the doses of TNF-α antagonists, 
particularly the highest dose of infliximab, were too high and that the inclusion criteria were 
too broad with NYHA heart failure class varying from II-IV in the study population (119).  
In patients with inflammatory arthropathies, no RCTs with TNF-α antagonists and 
cardiovascular endpoints have been conducted, and available results in this regard are from an 
observational study. Data from the Swedish biologics registry have indicated that anti-TNF-α 
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therapy reduces the incidence of first cardiovascular event in patients with RA (120). In line 
with this finding, Irace et al and Hürlimann et al have reported of improved endothelial 
function in patients with RA after initiation of anti-TNF-α therapy (27;121), and similar 
results have been reported in patients with systemic vasculitis (122). On the other hand, Van 
Doornum et al did not find any effect of TNF-antagonists on arterial stiffness assessed as the 
augmentation index (AIx, chapter 3.2.1) in their cohort of patients with RA (123). Knowledge 
about the duration of the possible favorable effect of TNF-α antagonists on vascular function 
in inflammatory arthropathies is limited. Although the endothelial function improved already 
the day after drug infusion in the study by Irace et al, the improvement was temporary, and all 
vascular parameters returned to baseline levels before the next infusion at weeks 2 and 6 (27). 
In accordance with this finding, Gonzales-Juanatey et al have shown a similar response in 
endothelial function after infliximab infusions in patients with RA who had been treated with 
infliximab for a minimum of a year (124). Thus, available data indicate a beneficial effect of 
anti-TNF-α therapy on endothelial function, but the long-term outcome and data on possible 
effects on arterial stiffness and CIMT are missing.   
1.6 Calprotectin  
Calprotectin is a heterodimer compounded by the S100A8 and S100A9 proteins, also referred 
to as Myeloid Related Proteins (MRP) 8 and 14 or calgranulin a and b (125). Calprotectin is 
mainly expressed in cells of myeloid origin, particularly in neutrophils, monocytes and 
macrophages in early differentiation states (126), and appears to have anti-microbial 
properties and a regulatory function in infections. Intracellular calprotectin plays an important 
role in myeloid cell maturation, cell trafficking and arachidonic acid metabolism (127). 
Activated phagocytes secrete the heterodimer (128), which induces chemotaxis and amplifies 
the pro-inflammatory cascade through interaction with surface receptors on target cells. 
Possible receptors for calprotectin include the receptor for advanced glycation end products 
(RAGE), heparin sulfate proteoglycans and carboxylated glycans (127). The intracellular 
signaling pathways activated by ligation of these surface proteins by calprotectin are not yet 
fully elucidated, but with respect to RAGE, the main pathway includes activation of NF-κB, 
which leads to enhanced expression of pro-inflammatory cytokines (127).  
Several inflammatory conditions are associated with high calprotectin plasma levels (127). In 
inflammatory arthropathies, calprotectin is associated with the disease activity and synovial 
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inflammation (129-131), and anti-TNF-α therapy has been demonstrated to reduce both the 
number of infiltrating MRP-8 and MRP-14 expressing macrophages in synovial tissue and 
serum levels of calprotectin (131). Furthermore, data indicate a role for calprotectin also in 
vascular endothelial dysfunction and progression of atherosclerostic lesions. Viemann et al 
have demonstrated that calprotectin increased transcription of pro-inflammatory chemokines 
and adhesion molecules and induced loosening of endothelial cell junctions (132). 
McCormick et al have demonstrated high expression of the protein complex in human plaque, 
but not in normal artery intima, and also high expression in calcifying areas (133). Only one 
previous study has examined associations between circulating calprotectin levels, CIMT and 
carotid plaques in the general population (134). This study did find that carotid plaque 
occurrence, but not CIMT, was positively associated with plasma calprotectin levels. Possible 
associations between arterial stiffness and circulating calprotectin have not been previously 
reported.  
1.7 ADMA 
Asymmetric dimethylarginine (ADMA) is an endogenous NOS inhibitor which is derived 
during posttranslational modification of arginine residues on various proteins that are 
predominantly found in the cell nucleus (135). ADMA impairs NO synthesis by competing 
with L-arginine as a substrate for NOS (136), and the relationship between ADMA and L-
arginine, usually expressed as the L-arginine/ADMA ratio, is suggested to be an important 
modulator of NOS activity (137;138). Intra-arterial infusions of ADMA or N-
monomethylarginine (L-NMMA) have been demonstrated to reduce the endothelium 
dependent vasodilatation in the human forearm (139) and to increase aortic stiffness and AIx 
(140;141). L-NMMA is another endogenous NOS inhibitor which is produced and degraded 
by the same pathways as ADMA, and is known to affect endothelial function just as powerful 
as ADMA. However, since plasma ADMA levels are tenfold greater than plasma L-NMMA 
levels (136), the majority of studies considering cardiovascular risk have focused on ADMA 
and the L-arginine/ADMA ratio (138). Plasma and serum ADMA levels have been 
demonstrated to be associated with cardiovascular risk factors such as hypertension (142), 
hypercholesterolemia (137), diabetes mellitus (143) and renal failure (144). ADMA was first 
demonstrated in patients with chronic renal failure by Vallance and coworkers (136), and 
have since then been shown to be an independent predictor of overall mortality and 
cardiovascular outcome in this population (145). Later reports have indicated that circulatory 
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ADMA levels also predict myocardial infarctions and cardiovascular events in patients with 
coronary artery disease (146;147) and recurrent cardiovascular events after percutaneous 
coronary intervention in patients who had presented with an acute coronary syndrome (148). 
The main catabolic pathways for ADMA are renal excretion and metabolism to L-citrulline by 
the enzyme dimethylarginine dimethylaminohydrolase (DDAH). Reduced renal excretion of 
ADMA in renal failure patients might explain some of the observed the increased 
cardiovascular risk in these patients. A previous in vitro study has shown that TNF-α 
increases ADMA concentration in endothelial cells by reduction of the activity of DDAH 
(149). The activity of DDAH strongly affects plasma ADMA levels (150). Circulating 
ADMA levels in patients with inflammatory arthropathies were scarcely examined at the time 
our project was designed. However, reduced endothelial function assessed as flow mediated 
dilatation (FMD) has been reported in these patients, and FMD has been demonstrated to 
improve during anti-TNF-α therapy (chapter 1.2, 1.3 and 1.5.2). Thus, increased ADMA 
levels induced by TNF-α’s effect on DDAH might contribute to the vascular pathology seen 
in inflammatory arthropathies, and anti-TNF-α therapy might be beneficial in this aspect by 
antagonizing this effect.  
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2 Aims   
2.1 General aim 
The general aim of this thesis was to examine the vascular effects of anti-TNF-α therapy in 
patients with inflammatory arthropathies, and to explore possible associations between 
changes in vascular function and structure and inflammatory markers.  
2.2 Specific research aims 
1. To explore the acute effects of infliximab infusions on arterial stiffness in patients 
with inflammatory arthropathies who are on long-term anti-TNF-α therapy (paper 1). 
2. To assess the short- and long-term effects of initiation of anti-TNF-α therapy on 
arterial stiffness in patients with inflammatory arthropathies (paper 2 and paper 3). 
3. To examine the effect of initiation of anti-TNF-α therapy on CIMT in patients with 
inflammatory arthropathies (paper 3).  
4. To assess the associations between circulatory inflammatory markers (CRP, 
erythrocyte sedimentation rate [ESR] and calprotectin), arterial stiffness (paper 1, paper 2 and 
paper 3) and CIMT (paper 3). 
5. To explore possible associations between measures of disease activity and arterial 
stiffness (paper 1, paper 2 and paper 3) and CIMT (paper 3).  
6. To assess the effect of anti-TNF-α therapy on circulating ADMA, L-arginine and the 
L-arginine/ADMA ratio, and whether possible changes in ADMA or L-arginine/ADMA are 
associated with arterial stiffness or CIMT (paper 4).   
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3 Patients, design and methods    
3.1 Patients and design 
3.1.1 Paper 1  
Seventeen patients with RA, AS or PsA and age > 18 years were recruited between February 
2006 and May 2006 from Diakonhjemmet Hospital (Oslo). All patients had been treated with 
infliximab for at least 12 months before inclusion. No control patients were recruited. The 
blood pressure of patients with arterial hypertension, defined as systolic pressure ≥ 140 
mmHg, diastolic pressure ≥ 90 mmHg or current use of antihypertensive medication, had to 
be well controlled (< 140/90 mmHg) for at least 6 months before the study start. Patients on 
lipid lowering treatment could only be included if they had been on a stable dose at least 6 
months prior to inclusion. Treatment with antihypertensive or lipid lowering medication had 
to remain unchanged during the study period. Patients who initiated treatment with other 
biological disease-modifying anti-rheumatic therapy such as treatment targeting B-cells 
(rituximab), T-cells (abatacept), interleukin-1 (anakinra) or interleukin-6 (tocilizumab) would 
be excluded. Further exclusion criteria were permanent cardiac arrhythmia or previous carotid 
surgery.  
The patients underwent arterial stiffness measurements, blood sampling and assessment of 
disease activity immediately before an infliximab infusion, and thereafter every 10th day until 
their next infusion. Infusion intervals of infliximab were determined by the patients’ clinical 
response to the treatment and varied from every 4th week to every 8th week. 
3.1.2 Paper 2, 3 and 4 
Patients with RA, AS or PsA and age > 18 years who were scheduled to initiate anti-TNF-α 
therapy due to the activity of their rheumatic disease were eligible for inclusion in the studies 
reported in paper 2, 3 and 4. Exclusion criteria were as for the patients in paper 1 (chapter 
3.1.1). Additionally, in paper 4 also patients with reduced kidney function or diabetes mellitus 
would be excluded. Sixty patients were recruited between June 2006 and January 2008 from 
Diakonhjemmet Hospital (Oslo) and Martina Hansens Hospital (Akershus). Fifty-eight of the 
60 patients included in the studies were TNF-α antagonist drug naïve; two patients had 
previously (> 18 months before inclusion) used a TNF-α antagonist, but had ended treatment 
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due to failure or allergic reaction. The patients were asked about a possible study participation 
after their clinical indication for therapy had been established, but prior to the pre-treatment 
examinations (e.g. Mantoux’ test, screening for heart failure and hepatitis). We expected that 
some of the patients would have to postpone therapy initiation due to findings in their pre-
treatment examinations that required further evaluation, their working situation or planned 
operations. We had pre-specified that these patients would serve as controls for the total 
follow-up period or until they started with a TNF-α antagonist. Follow-up was one year after 
initiating anti-TNF-α therapy, or one year from the baseline examination for the control 
patients who did not initiate this therapy. The patients in the control group were not scheduled 
to receive specified alternative treatment, and each patient’s treating rheumatologist was free 
to adjust medication in accordance with the disease activity.  
In paper 2, we reported the short-term (3 months) effects of anti-TNF-α therapy on arterial 
stiffness. Because we in this thesis intended to explore both the short-term and the long-term 
(one year) effects of anti-TNF-α therapy on arterial stiffness, and since we expected that 
several of the patients in the control group would start therapy after a couple of months, we 
had pre-specified an evaluation of changes in arterial stiffness after 3 months. At this time 
point, none of the patients had dropped out, and the 35 patients who had started with anti-
TNF-α therapy were compared to a non-treatment group of 25 patients. Both the anti-TNF-α 
group and the control group underwent assessments of arterial stiffness and disease activity 
and blood sampling at baseline and after 3 months.  
Five patients terminated the study before a follow-up after one year. Three patients were 
excluded because they initiated treatment with rituximab or anakinra. One patient ended anti-
TNF-α therapy because of suspected cancer, and another because of an allergic reaction. 
Thirty-six patients continued anti-TNF-α treatment for one year, and 19 patients remained 
without anti-TNF-α treatment during a total follow-up of one year. All these patients 
underwent measurements of arterial stiffness, disease activity and blood sampling at baseline 
and every third month until one year. Additionally, CIMT was assessed at baseline, 6 months 
and one year. In paper 3 we reported the effects of one-year anti-TNF-α therapy on arterial 
stiffness, CIMT and circulating calprotectin. In paper 4 we reported the effects of anti-TNF-α 
therapy on ADMA, L-arginine and L-arginine/ADMA, which were analyzed from plasma 
samples taken at the baseline, 3 and 12 months visits. 
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3.2 Methods 
3.2.1 Arterial stiffness  
Arterial stiffness can be assessed as local, regional or systemic stiffness with a large selection 
of devices (20). We measured the carotid-femoral pulse wave velocity and the AIx with the 
Sphygmocor device version 7.1 (AtCor Medical, Sydney, Australia) and a validated 
tonometer (SPC-301; Millar instruments, Houston, USA). Arterial stiffness examinations 
were conducted in concordance with the standardizations recommended in the expert 
consensus document on arterial stiffness (20). 
Carotid-femoral pulse wave velocity is recognized as a measure of aortic pulse wave velocity 
(aPWV), and is currently accepted as the gold standard measurement of arterial stiffness (20). 
aPWV is the speed at which the pulse pressure wave travels down the aorta, and is thus an 
assessment of regional aortic stiffness. For the evaluation of aPWV, carotid and femoral 
artery waveforms were sequentially recorded with tonometry and the transit time was 
calculated by the integrated software using simultaneously recorded ECG as reference (151). 
The wave travel distance was obtained by subtracting the distance from the carotid location to 
the sternal notch from the distance between the sternal notch and the femoral site of recording 
(20). aPWV has been demonstrated to be a predictor of CVD in several patient groups with 
different cardiovascular risk factors such as hypertension, diabetes and hypercholesterolemia 
and in the general population (20). Increased stiffness of the aorta and carotid arteries have 
previously been demonstrated in patients with RA (23;24). Furthermore, aPWV has been 
demonstrated to change both during anti-inflammatory treatment in patients with vasculitis 
(122) and as a response to a mild systemic inflammation induced by vaccination in a healthy 
group of subject (38). The change in aPWV in the latter study was measurable already eight 
hours after the vaccination, thus demonstrating that aPWV may change rapidly in relation to 
an inflammatory stimulus (38).  
AIx is a measure of pulse wave reflection (20). The arterial pressure waveform is considered 
to be a composite of the forward pressure wave generated by the left ventricular contraction 
and the waves reflected from the arterial periphery. AIx refers to the difference between the 
second and the first systolic peaks of the waveform, expressed as a percentage of the pulse 
pressure (20).  AIx is dependent on the magnitude and site of pulse wave reflection and the 
speed of the reflected wave. Thus, AIx is influenced by arterial stiffness, but also peripheral 
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vascular resistance (152). To obtain the AIx, peripheral pressure waveforms were recorded 
from the radial artery at the wrist with the tonometer. Corresponding central aortic waveforms 
were generated by integrated software from which central hemodynamics and aortic AIx were 
calculated (153). AIx has been demonstrated to be a predictor of all-cause mortality in 
patients with kidney failure and of cardiovascular events in patients with hypertension, stable 
angina or acute coronary syndromes (20). AIx has been shown to be increased in patients with 
RA compared to healthy controls (22), and to be a more sensitive measure of vascular 
dysfunction than brachial FMD in this patient population (25). 
3.2.2 Carotid intima media thickness  
CIMT is a measure of the combined thickness of the intima and media layers, the two layers 
closest to the vessel lumen, in the carotid artery. We measured CIMT in the common carotid 
artery on both sides of the neck. The common carotid artery was visualized in a longitudinal 
view and scanned for plaques before CIMT was assessed. CIMT measurements were 
performed in the far wall of approximately 2 cm long segments free of plaques in the distal 
common carotid artery close to the carotid bulb (154). During examination, the patient’s neck 
was slightly hyperextended and the head rotated in the opposite direction of the probe. To 
standardize the position of measurements at the consecutive visits a protractor frame was 
used. CIMT was assessed with the multiarray echotracking system Art.Lab (Esaote, 
Maastricht, the Netherlands) equipped with a 5-10 MHz linear array transducer (155). The 
system utilizes rough radio frequency data to automatically register intima media thickness of 
the common carotid artery for each subsequent cardiac cycle over a period of 6 seconds (156). 
The rough radio frequency data were analyzed both online and from the 6-second stored 
cineloops.  
CIMT has been demonstrated in several studies to be a marker of the generalized 
atherosclerotic burden and a predictor of cardiovascular disease (154;157). Furthermore, 
CIMT is a validated surrogate endpoint for cardiovascular disease in intervention trials, 
particularly in studies with statins or anti-hypertensive medication (64;158;159).  CIMT has 
been demonstrated to be associated with markers of systemic inflammation both in the general 
population and in patients with RA (32;40;160), but results regarding an effect of anti-
inflammatory treatment on CIMT progression have been missing. On average, the follow-up 
time before an observable change in CIMT after initiation of medical treatment seems to be 
one to two years (64). However, a small study exploring the effect of statin treatment on 
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carotid and femoral artery intima media thickness has demonstrated significant changes 
already after 8 weeks of treatment (161). The authors of this study attributed the rapid 
improvement in carotid and femoral intima media thickness to the anti-inflammatory effect of 
statins.  
3.2.3 Disease activity  
The clinical status and disease activity were evaluated according to the American College of 
Rheumatology’s preliminary core set of disease activity measures for RA clinical trials (162). 
Our assessments included counts of tender and swollen joints, measurement of acute phase 
reactants (ESR and CRP), physician’s evaluation of global disease activity on a 100 mm 
visual analog scale (VAS), and the patients’ assessment of pain and global disease activity on 
100 mm VASs and evaluation of physical function with the Health Assessment Questionnaire 
(HAQ). We also obtained the patients’ assessment of fatigue on a 100 mm VAS. The disease 
activity score based on 28 joints (DAS 28) and ESR (DAS28 = 0.56 √[number of tender 
joints] + 0.28 √[number of swollen joints] + 0.70 Ln [ESR] + 0.014 [patient’s evaluation of 
global disease activity on a VAS]) (163) was computed in the patients with RA. 
3.2.4 Laboratory Measurements  
Fasting blood samples were collected at all visits. ESR was analyzed by the Westergren 
method. Hemoglobin (Hb), total cholesterol, LDL, high density lipoprotein cholesterol, 
triglycerides, CRP and creatinine were determined by standard methodology at the time of 
examinations (Sysmex Corporation, Kobe, Japan and Roche Diagnostics GmbH, Mannheim, 
Germany). For analyses of calprotectin, ADMA and L-arginine, EDTA plasma samples were 
stored at −80°C and thawed at room temperature before the analyses. Calprotectin was 
determined with ELISA kits from Calpro AS, Lysaker, Norway. L-arginine and ADMA were 
determined by high performance liquid chromatography and precolumn derivatization with o-
phthaldialdehyde (Sigma Chemicals Co, St.Louis, MO).   
3.2.5 Statistics 
Continuous data are presented as mean with standard deviation (SD), median with quartile 
cut-points (25th and 75th percentiles) or geometric means with 95% confidence intervals as 
appropriate. Between group differences were compared using Student’s t-test for independent 
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samples or with Mann-Whitney U test when data were skewed. Within group changes were 
assessed by paired Student’s t-test or Wilcoxon signed-rank test. Categorical variables are 
expressed as numbers and were compared using Pearson’s χ² test. Bivariate relations were 
analyzed using Pearson’s, or in the case of skewed variables, Spearman’s correlation 
coefficient. 
Analyses of covariance (ANCOVA) were used to in paper 2 to explore associations between 
the baseline value and change in aPWV with CRP and change in CRP as both a continuous 
variable and categorized into quartiles. In paper 4, baseline associations with aPWV were 
determined with multivariable linear regression analyses. 
For determinants of change in aPWV in paper 2, a robust multivariable regression analysis 
was performed, because of non-normality of the residuals.  
Multivariable mixed model repeated measure linear regression analyses were used to examine 
associations between aPWV, AIx, CIMT, ADMA, L-arginine/ADMA, markers of 
inflammation and disease activity in paper 1, 3 and 4. The effects of anti-TNF-α therapy in 
paper 3 and 4 were examined as the interaction between the variables anti-TNF-α therapy and 
time. Mixed model repeated measures analysis is a longitudinal linear regression analysis that 
controls for multiple testing of the same patient by modeling the covariance between the 
repeated measurements of each individual as a clustered random effect. An unstructured 
covariance matrix was used in our analyses assuming that the correlation for each level of 
within-subject factor was different. The mixed model procedure deals with missing values by 
assuming them to be missing at random without removing the individual from the dataset.  
Bivariate analyses of clinically important covariates were performed, and covariates with P-
value < 0.25, or covariates known to influence the respective dependent variables, were 
entered into the multivariable models. Variables were then removed in a step-down manner 
according to levels of significance as described by Hosmer and Lemeshow (164). The models 
were examined for relevant interactions and confounding in a standard manner.  
Due to the non-randomized setting of our studies, the multivariable analyses in paper 2 and 3 
were repeated after a one to one matching of the patients in the control group with a similar 
numbers of patients in the treatment group by age, sex and mean arterial pressure (MAP). 
Age, sex and blood pressure are some of the most important predictors of aPWV, AIx and 
CIMT (20;154). In the analysis of the matched pairs in paper 2, a two-way analysis of 
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variance (ANOVA) with randomized blocks was applied. In paper 3, the mixed models 
analyses were repeated after matching with the matched pairs included as a random factor. 
Standardised response mean values (mean change from baseline / SD of the change) were 
used to illustrate the magnitude of the response in key variables after three 3 months in paper 
2. Standardised response mean values were interpreted as effect sizes according to Cohen 
(165); standardised response means ≥0.2 and < 0.5, ≥0.5 and <0.8, and≥0.8 indicate small, 
moderate and large magnitudes of change, respectively.  
All statistic tests were two-sided and P-values ≤ 0.05 were considered significant. Statistical 
analyses were performed with Statistical Package for the Social Sciences (SPSS), version 
16.0-18.0 (SPSS Inc., Chicago, USA) and R (R Development Core Team (2008). R: A 
language and environment for statistical computing. R Foundation for Statistical Computing, 
Vienna, Austria). A statistician was consulted regarding the statistical analyses in this thesis.  
3.3 Ethical aspects 
Approval was obtained from the regional research ethics committee, and written informed 
consent was obtained from each participant. The Norwegian social science data services gave 
permission to the storage of research data, and authorization to store biological material was 
granted by the Directorate of Health. All studies were performed according to ethical 
principles of the declaration of Helsinki. 
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4 Summaries of results 
4.1 Paper 1 
Changes in arterial stiffness during continued infliximab treatment in patients with 
inflammatory arthropathies. 
The aim of this study was to evaluate arterial stiffness and disease activity between two 
infusions of infliximab in patients with inflammatory arthropathies who had been treated with 
this drug for at least 12 months prior to inclusion in the study. AIx, aPWV and disease activity 
were measured in 17 patients immediately before an infliximab infusion and thereafter every 
10th day until their next infusion scheduled at week 4-8. AIx and aPWV did not change 
during the period between the infliximab infusions. The patients had a temporary 
improvement in the global disease activity assessed on VAS by the patients (P= 0.04) and the 
investigator (P= 0.02) after the infusion. In the group of patients with RA, the DAS28 
changed in a similar manner (P= 0.003). CRP and ESR remained unchanged. Multivariable 
repeated mixed model analyses showed no longitudinal associations between AIx, aPWV, 
measures of disease activity, CRP or ESR. These findings were confirmed with analyses on 
the individual level with line charts. 
4.2 Paper 2 
Tumor Necrosis Factor-α antagonists improve aortic stiffness in patients with 
inflammatory arthropathies: A controlled study.  
The purpose of this study was to evaluate the effect of treatment with TNF-α antagonists on 
arterial stiffness after three months in patients with inflammatory arthropathies. Changes in 
aPWV and AIx were examined in 35 patients who had started with anti-TNF-α therapy and in 
25 non-treated patients. aPWV (mean [SD]) was reduced in the treatment group, but not in the 
control group (-0.50 [0.78] m/s versus 0.05 [0.54] m/s, respectively; P=0.002).  Reductions in 
aPWV were seen in both the patients with RA, AS and PsA and in subgroups according to use 
of various TNF-α antagonists. Central pressures and AIx remained unchanged in both the 
treatment and the control group. CRP and DAS28 were significantly reduced in the treatment 
group (-9.3 [20.2] mg/L, P<0.001 and -0.74 [0.91], P=0.004). In an ANCOVA analysis with 
change in CRP categorized into quartiles, patients with the largest reduction in CRP had a 
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significant greater reduction in aPWV after 3 months than the patients in the lowest quartile (-
0.63 [0.75] m/s versus 0.06 [0.60] m/s, respectively; P=0.01), but the overall model was not 
significant (P=0.08). The change in aPWV and the inflammatory markers in the two patient 
groups were further compared with standardised response means, which demonstrated a 
moderate-to-high responsiveness (standardised response mean >0.50) in aPWV, CRP, ESR, 
and DAS28 to anti–TNF-α therapy. In a multiple linear regression model only treatment with 
TNF-α antagonist (β=-0.485, P=0.003) and change in MAP (β=0.029, P=0.008) were 
associated with alterations in aPWV. In a repeated analysis after matching patients in the two 
groups by sex, age and MAP, anti-TNF-α therapy remained significantly associated with 
change in aPWV (β=-0.675, P=0.0045).  
4.3 Paper 3 
Effect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis and 
calprotectin in inflammatory arthropathies: A controlled study. 
The objective of this study was to examine the effect of one year of treatment with TNF-α 
antagonists on arterial stiffness and CIMT progression in patients with inflammatory 
arthropathies, and possible associations to calprotectin. Fifty-five patients were followed with 
regular examinations for one year. Thirty-six patients starting with anti-TNF-α therapy were 
compared with a non-treatment group of 19 patients. After one year, aPWV (mean [SD]) was 
improved in the treatment group, but not in the control group (-0.54 [0.79] m/s vs. 0.06 [0.61] 
m/s, P=0.004), and CIMT progression (median [quartile cut-points, 25th and 75th 
percentiles]) was reduced in the treatment group compared to control group (-0.002 [-0.038, 
0.030] mm vs. 0.030 [0.011, 0.043] mm, P=0.01). The main change in aPWV occurred the 
three first months after initiation of anti-TNF-α therapy, but aPWV remained at a stable lower 
level in the treatment group compared to the control group during the entire follow-up period. 
Measures of inflammatory activity including calprotectin improved significantly in the 
treatment group. In multivariable repeated mixed model analyses, anti-TNF-α therapy over 
time was associated with improved aPWV (P=0.02) and reduced CIMT progression (P=0.04), 
and calprotectin was longitudinally associated with aPWV (P=0.02). The results from the 
multivariable analyses did not change after matching the patients for age, sex and MAP.  
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4.4 Paper 4 
The L-arginine/asymmetric dimethylarginine ratio is improved by anti-Tumor Necrosis 
Factor–α therapy in inflammatory arthropathies. Associations with aortic stiffness. 
The purpose of this study was to examine the effect of treatment with TNF-α antagonists on 
ADMA and L-arginine/ADMA in patients with inflammatory arthropathies. Furthermore, we 
sought to explore possible associations between ADMA, L-arginine/ADMA, arterial stiffness 
and CIMT. Thirty-six patients who started with anti-TNF-α therapy and continued this 
treatment for one year were compared with a non-treated group of 19 patients. Plasma ADMA 
and L-arginine, aPWV and AIx were assessed at baseline, 3 and 12 months.  CIMT was 
measured at baseline and 12 months. Anti-TNF-α therapy for 12 months increased the L-
arginine/ADMA ratio (mean [SD]) in the anti-TNF-α group compared to the control group (9 
[30] vs. -7 [22], P=0.03), but did not change ADMA (0.01 [0.09] μmol/L vs. 0.00 [0.09] 
μmol/L, P=0.88). Baseline aPWV was associated with ADMA (P=0.02) and L-
arginine/ADMA (P=0.02) in multiple linear regression analyses, and the L-arginine/ADMA 
ratio was continuously associated with aPWV after initiation of anti-TNF-α therapy in a 
multivariable mixed analysis (P=0.03). L-arginine, ADMA and L-arginine/ADMA were not 
associated with any of AIx, central blood pressures or CIMT.  
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5 General discussion 
5.1 Methodological considerations 
5.1.1 Study design and patients 
The knowledge about the natural development in measures of vascular function and structure 
in patients with inflammatory diseases over time, and also how individual fluctuation in 
disease activity would affect these measures, were scarcely examined at the time we 
conducted our studies. We therefore included a control group of patients who did not receive 
anti-TNF-α therapy but who had similar inflammatory activity and indication for this therapy 
as those in the treatment group for the studies reported in paper 2, 3 and 4. Obviously, the 
optimal design would have been to randomize to anti-TNF-α therapy or placebo. However, 
we did not find this design ethically acceptable as all patients had a clinical indication for 
treatment with TNF-α antagonists according to accepted recommendations for such treatment 
(166). Only one previous study exploring vascular effects of anti-TNF-α therapy in patients 
with inflammatory arthropathies has applied a randomized design (167). In that study, all 
patients in the non-TNF-α antagonist group had switched to the treatment group before the 
vascular evaluation was performed. This observation illustrates the difficulties of conducting 
a randomized study with anti-inflammatory treatment assessing cardiovascular endpoints in 
patients with inflammatory arthropathies. Our choice of control group could have introduced 
potential bias, i.e. such as a tendency to more active disease in the treatment group or a higher 
rate of co-morbidities in the control group. However, we could not detect that any of these 
factors influenced our results. The treatment group and the control group were recruited from 
the same clinical setting and the two patients groups did not differ with regard to demographic 
characteristics, baseline disease activity or co-morbidities (paper 2, 3 and 4). Nevertheless, we 
chose to repeat the statistical multivariable analyses after matching patients in the two 
treatment groups by sex, age and MAP. New analyses after matching for these parameters did 
not meaningfully change the results (paper 2 and 3).  
We included three types of inflammatory arthropathies in our studies. RA, AS and PsA are all 
associated with an increased cardiovascular risk, and good efficacy of anti-TNF-α is 
demonstrated in all diseases. Whereas the CVD risk in RA has been known for some years 
(chapter 1.2), the cardiovascular co-morbidity in AS and PsA has gained increasing attention 
the recent years. Excess risk of myocardial infarction has been demonstrated in both 
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conditions (168-170), and Hollan et al have reported that a diagnosis of AS or PsA was a 
stronger predictor for early coronary artery bypass grafting than most traditional 
cardiovascular risk factors (171). Accordingly, several studies have shown increased levels of 
vascular dysfunction in AS and PsA (48;172-177), whereas results regarding CIMT have been 
more inconsistent (48;173;176;178-185). The prevalence of CVD in AS and PsA has in one 
study been shown to resemble that of RA (186), whereas others report of  a somewhat lower 
risk in AS and PsA compared to RA (170). These results indicate that an increased 
cardiovascular risk and premature vascular pathology not are restricted to RA, but also applies 
to AS and PsA. Recent studies have confirmed an equally good efficacy of anti-TNF-α 
therapy with regard to health related quality of life and drug retention rates in AS and PsA 
compared to RA (187-189). Anti-TNF-α therapy does not seem to have the beneficial effect 
on new bone formation in AS which has been demonstrated for the erosive bone destruction 
in RA and PsA (190). However, a rapid effect on joint inflammation and cellularity (chapter 
1.5.2) and circulatory inflammation, which probably are more important with regard to 
vascular pathology, is demonstrated in both RA, AS and PsA (191). Nevertheless, including 
RA, AS and PsA made the total population more heterogeneous, and the diseases have 
differences in both treatment options (chapter 1.5) and disease pathology (chapter 1.1), which 
could have influenced our results. The effects of anti-TNF-α therapy on the vascular 
endpoints in our studies were comparable and the reductions in aPWV were significant within 
the different diagnose groups (paper 2 and 3). Furthermore, the multivariable statistical 
analyses did not reveal that type of rheumatic diagnosis or TNF-α antagonists influenced our 
results (paper 1, 2 and 3). Nonetheless, this project was not powered or designed to examine 
differences between the RA, AS and PsA subgroups and significant differences between these 
groups cannot be fully excluded. As illustrated in the online supplementary information file 3 
to paper 3, AS patients seemed to have a smaller reduction in aPWV than patients with RA 
and PsA, although the changes in the three groups were not significantly different. However, 
the AS patients in the treatment group in paper 3 were younger and had lower blood pressure 
than the RA and PsA patients (unpublished data). As recently reported by the reference values 
for arterial stiffness collaboration, age and blood pressure are the main determinants for 
aPWV (192). Age and blood pressure were significantly associated with aPWV also in our 
population (paper 3). Therefore, differences in age, baseline blood pressure and aPWV may 
explain a possible unlike effect of anti-TNF-α therapy on aPWV in AS patients compared to 
RA and PsA patients. The possible difference in the change in aPWV could also be explained 
by a lower baseline inflammatory activity in the AS patients compared to the RA and PsA 
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patients. The patients with AS could have initiated anti-TNF-α therapy at lower disease 
inflammatory activity than patients with RA or PsA due to lack of other therapeutic options 
(chapter 1.5). In the treatment group, patients with AS had lower calprotectin levels than both 
RA and PsA patients, similar ESR as PsA patients but lower than RA patients, and similar 
CRP values as both RA and PsA patients (unpublished data). Consequently, including patients 
with AS might have reduced the beneficial effect on vascular parameters, but also these 
patients had a significant reduction in aPWV and a similar timing of the change as the RA and 
PsA patients (paper 2 and 3).  
We also included three different types of anti-TNF-α treatment in the studies reported in 
papers 2, 3 and 4 (chapter 3.1.2), and similar objections may be raised against this choice as to 
the inclusion of different types of inflammatory arthropathies. The numerical effect of the 
different TNF-α were similar, and multivariable statistical analyses did not reveal that type of 
TNF-α antagonists influenced our results (paper 2 and 3).  
5.1.2 Methods  
Different techniques and devices can be used both for arterial stiffness and CIMT 
measurements, and methodological choices clearly influence the obtained values (154;192). 
We measured aPWV using the pulse wave travel distance obtained by the subtraction method, 
which give results that differ from results obtained with other ways of assessing the pulse 
wave travel distance. Furthermore, our CIMT values were calculated automatically and given 
as the average CIMT during the whole cardiac cycle, and may thus differ from values 
obtained with manual or semi-automatic reading or in end diastole (193). These aspects are of 
special importance when aPWV and CIMT values are compared cross-sectionally with 
previous obtained values. Our primary endpoints were, however, the changes in the vascular 
parameters. Since these methodological differences are constant between each visit, they are 
of less importance in the interpretation of longitudinal results.  
All vascular measurements reported in this thesis were done by the same examiner and with 
identical devices at every visit. Our repeatability results demonstrated a high intra-reader 
correlation coefficient, acceptable limits of agreement and consistent Bland Altman-plots for 
repeated measures of AIx, aPWV and CIMT (paper 3). 
Infliximab, etanercept and adalimumab are administered with different time intervals. 
Infliximab is after the two first months usually given every 8th week, etanercept once or twice 
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weekly and adalimumab every other week. Therefore, the vascular examinations were 
conducted with different time relations to the last drug administration according to which drug 
the patients was using. In light of the previously demonstrated transient effect of infliximab 
on endothelial function (chapter 1.5.2) (27;124), this could have affected our results. We did, 
however, not demonstrate any effect of infliximab infusions on AIx or aPWV in our patients 
who were on long-term treatment and had stable low CRP and ESR levels (paper 1). 
Furthermore, any effects due to differences in timing between drug administrations and the 
vascular measurements would be by chance and would not systematically affect the results.  
DAS28, VASs and HAQ are all important outcome measures in clinical trials in patients with 
inflammatory arthropathies. However, these measures may be influenced by co-morbidities, 
personal factors, pain and chronic joint damage, and thus not only reflect the present 
inflammatory activity of the rheumatic disease (194). Furthermore, particularly the patient 
reported outcomes may have been influenced by the open label design of our studies.  
Disease activity scores specific for AS and PsA equivalent to the DAS28 in RA were not 
reported in this thesis. The motivation for this choice was an intention to focus on disease 
activity measures that were assessable in all three groups of patients due to the small patient 
populations. Nevertheless, we reported the DAS28 in patients with RA since this was the 
largest group of patients and because this measure had been reported in the previous studies 
examining responses in vascular function to anti-TNF-α therapy (27;121). Importantly, the 
latest composite scores for assessment of AS and PsA were not available when this research 
work was started (195-197). 
5.2 Discussion of main findings 
5.2.1 The effect of TNF-α antagonists on vascular function and structure  
We showed in our studies that TNF-α antagonists have a beneficial effect on both vascular 
function (aPWV, the L-arginine/ADMA ratio) and vascular structure (CIMT) (paper 2, 3 and 
4) in patients with inflammatory arthropathies.   
With regard to effects of anti-TNF-α therapy on vascular function, other groups have reported 
findings in line with ours during the recent years (167;177;198-201). The majority of these 
studies have assessed the effect on FMD, which is a measure of endothelial function, whereas 
only two studies besides ours have explored changes of anti-TNF-α therapy on aPWV 
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(167;200). Maki-Petaja et al demonstrated a reduction in aPWV after twelve weeks of therapy 
in a group of nine patients with RA (200) and Wong et al showed an improvement in aPWV 
in sixteen RA patients after 56 weeks of anti-TNF-α therapy (167). To our knowledge, data on 
anti-TNF-α therapy’s effect on ADMA and L-arginine have been missing. We demonstrated 
that anti-TNF-α therapy increased plasma L-arginine and the L-arginine/ADMA ratio, but had 
no effect on ADMA (paper 4). These findings are in accordance with two recently published 
cross-sectional studies which have reported that current use of TNF-α antagonist did not 
influence plasma ADMA levels in patients with AS (202;203).  
AIx, which is another measure of vascular function, did not change after initiation of anti-
TNF-α therapy in our population (paper 2 and 3). Although Galarraga et al recently have 
reported improvement in AIx after two months of treatment with etanercept in patients with 
RA (204), our finding is in concordance with the majority of previous studies 
(123;167;184;200;205). One possible explanation to these observations is that the reduction in 
systemic inflammation induces peripheral vasoconstriction, or normalisation of the 
vasculature’s tonus. Peripheral vasodilatation is a well-known feature of infectious and 
inflammatory diseases. The change in peripheral vascular tonus may result in pulse wave 
reflection points closer to the heart or change in the magnitude of wave reflection, and the 
consequent modifications in wave reflections would thus counteract the influence of the 
reduced aPWV on AIx. In line with this explanation, AIx has been demonstrated to decrease 
simultaneously with an increase in aPWV during a vaccination induced low-grade 
inflammation in a group of healthy subjects (38). Furthermore, infliximab infusions in 
patients with RA have been shown to reduce the brachial artery’s diameter (27).  
Current data on TNF-α antagonists’ effect on vascular structure such as CIMT are more 
inconsistent than the results on vascular function. Wong et al, Sidiropoulos et al and 
Gonzalez-Juanatey et al did not find any effect of anti-TNF-α therapy on CIMT in patients 
with RA (167;201;206). In contrast, two larger studies, which included RA patients receiving 
standard therapy as controls, have shown a reduction in CIMT after such treatment (207;208). 
The majority of results from trials with statin and anti-hypertensive treatment and CIMT as 
endpoint indicate that the effect after medical intervention on CIMT most often is a reduced 
progression and not an actual reduction in the treatment group (158;159). These results 
emphasize the importance of a control group in studies evaluating CIMT, and might be a part 
of the explanation of the negative findings in the studies by Wong et al, Sidiropoulos et al and 
Gonzalez-Juanatey et al (167;201;206).   
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We demonstrated that aPWV was reduced in the treatment group at the first follow-up visit at 
3 months (paper 2 and 3) and that this beneficial treatment effect was maintained throughout 
the one-year follow-up period (paper 3). The reference values for arterial stiffness 
collaboration has recently published pulse wave velocity normal and reference values 
according to age and blood pressure category (192). In our one-year follow-up study, the 
patients in the treatment group were on average 47.2 years old and their mean blood pressure 
was 131/79 mmHg  (paper 3). According to the reference values the expected mean aPWV 
value in these patients would be 6.6-7.0 m/s. The mean aPWV in the treatment group after 
one year was 6.94 m/s. Thus, one possible interpretation of our results would be that anti-
TNF-α therapy reduced aPWV to the expected level for a subject without systemic 
inflammation. Furthermore, this explanation is supported by our observation of the stable 
aPWV measurements in patients on long-term infliximab therapy (paper 1) and by Maki-
Petaja et al’s demonstration of a reduction in aPWV to the level of healthy controls after 
twelve weeks of anti-TNF-α therapy (200). 
Structural alterations such as changes in CIMT during intervention trials are normally not 
detectable before one year of follow-up, and would be expected to follow a more regular 
pattern than changes in vascular function (64). The effect of treatment with a TNF-α 
antagonist on CIMT in our population was comparable with that reported in studies evaluating 
the efficacy of statin therapy on far wall CIMT (64). In a previous meta-analysis, statin 
therapy was associated with an average decrease in CIMT progression of 0.012 mm/year 
(158). CIMT increases with age, also in healthy subjects without risk factors for 
atherosclerosis (154), and a small progression in CIMT in the control group was expected. 
The observed increase in CIMT in the control group in our population was in the upper level 
of a normal increase after one year (64).  
We showed in our population that baseline aPWV was associated with plasma ADMA and L-
arginine/ADMA levels. Previous data on an association between the L-arginine/ADMA ratio 
and aPWV or AIx both in inflammatory arthropathies and other populations have been 
missing, whereas the existing results regarding relations between circulatory ADMA and 
aPWV or AIx have been inconsistent. AIx has been demonstrated to correlate with ADMA in 
patients referred to elective percutaneous coronary intervention and in the general population 
(209;210), whereas studies in hypertensive patients and another study in the general 
population demonstrated no relation (210-212). None of these studies have demonstrated a 
correlation between aPWV and ADMA. In patients with inflammatory arthropathies, one 
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study has reported of an inverse correlation between circulatory ADMA levels and coronary 
flow reserve (213), whereas another study has showed no association between brachial artery 
FMD and ADMA (202). However, the latter study included patients who were on treatment 
with a TNF-α antagonist. Anti-TNF-α therapy has been demonstrated to improve FMD 
(27;121;200), and inclusion of these patients may have reduced a possible correlation between 
FMD and ADMA. In our population, the greatest change in both aPWV and the L-
arginine/ADMA ratio took place during the three first months after initiation of anti-TNF-α 
therapy (Paper 3 and 4), and the L-arginine/ADMA ratio was continuously associated with 
aPWV after initiation of TNF-α antagonists. Thus, improvement in NO availability 
subsequent to increase in the L-arginine/ADMA ratio may be involved in the favorable effect 
of anti-TNF-α therapy on aPWV in our population.  
Previous studies indicate that circulating ADMA levels are associated with CIMT 
(211;214;215) and predict CIMT progression (214) in the general population, although a large 
cross sectional study within the Framingham heart study offspring cohort found significant 
associations only to internal carotid artery and carotid bulb intima media thickness and not to 
CIMT (216). In patients with inflammatory arthropathies, data regarding correlations between 
ADMA and CIMT are inconsistent (202;213;217). We did not observe any associations 
between CIMT and ADMA, L-arginine or the L-arginine/ADMA ratio. However, the patients 
in our study had CIMT values in the lower normal range. Therefore, correlations between 
CIMT and L-arginine/ADMA or ADMA may be easier to evaluate in patient groups with 
more pronounced atherosclerosis than in our cohort, and in larger patient groups.  
Inflammation may promote vascular pathology and CVD through direct effects on the artery 
wall (chapter 1.4), but also by influence on traditional risk factors such as serum lipids, 
insulin resistance (37), or blood pressure (218). As discussed in chapter 1.2-1.3, inflammatory 
arthropathies are associated with increased levels of cardiovascular risk factors such as 
smoking, dyslipidemia, insulin resistance and, as recently reported, an increased prevalence of 
hypertension (219). Data regarding the effect of anti-TNF-α therapy on quantitative serum 
lipid levels have been inconsistent, particularly in long-term studies. It seems overall that this 
treatment improves the atherogenic index during the first months of therapy, but results 
obtained after longer treatment periods are divergent (220;221). Regarding the effect of anti-
TNF-α therapy on blood pressure, Klarenbeek et al have recently published blood pressure 
data from the BeSTstudy in which RA patients were randomized to four different types of 
anti-rheumatic treatment strategies (222). One of these strategies included a TNF-α antagonist 
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(infliximab), and the results demonstrated that anti-TNF-α therapy had a favorable effect on 
blood pressures compared to the other anti-rheumatic therapy options. We did not find any 
significant changes in blood pressures or standard serum lipids in our studies. Thus, our 
findings might support previous results of a beneficial effect of anti-inflammatory treatment 
on vascular pathology beyond the influence on traditional cardiovascular risk factors in 
inflammatory arthropathies.  
Altogether, available results indicate a beneficial effect of TNF-α antagonists on vascular 
function and structure in inflammatory arthropathies. This interpretation is in line with two 
recently published reviews and one American registry study of anti-TNF-α therapy’s effect on 
CVD in patients with RA, which concluded that such therapy appears to have a favourable 
effect (223-225). However, most of the previous studies that have examined vascular effects 
of anti-TNF-α therapy have small patient numbers, which may raise the possibility of 
publication bias, and RCTs in this field are lacking (1.5.2).  
5.2.2 Relations between vascular measurements and inflammatory markers  
Vascular pathology has previously been demonstrated in cross sectional examinations to 
correlate with disease duration and/or markers of inflammation in patients with RA and in the 
general population (200;226;227). Our research group have recently demonstrated in another 
cohort of patients with RA that augmented CRP levels predicted increased aPWV and AIx 
(228), and that aPWV was lower in patients with low disease activity compared to those with 
active disease (229). As expected, the patients who started anti-TNF-α therapy in the present 
studies had a significant improvement in both biochemical inflammatory markers and clinical 
disease activity measures (paper 2 and 3). These findings are in accordance with previously 
published studies, which have demonstrated improvement in vascular function and structure 
concurrent with reduction in several inflammatory and disease activity markers such as CRP, 
ESR, DAS28 and patients’ global assessment of disease activity on VAS 
(27;121;124;167;200;201;207;208;230).  
We could not demonstrate any significant correlations between changes in aPWV or CIMT 
and CRP, ESR, DAS28, the VASs or HAQ (paper 1, 2 and 3). In concordance with our 
results, the majority of other studies also report of parallel reductions in measures of 
inflammatory activity and vascular pathology, but no correlations 
(27;121;124;167;200;201;208;230). The lack of associations in our studies may very well be 
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related to the size of the patient groups since changes in aPWV after three months of anti-
TNF-α therapy showed a tendency to correlate with change in CRP during the same time 
frame (paper 2). In line with this interpretation, a recent review of articles addressing the 
association between CIMT and soluble markers of inflammation, endothelial damage and 
hemostasis concluded that of soluble biomarkers only CRP and fibrinogen seemed to be 
related to CIMT, but that such associations only were demonstrable in cohorts consisting of 
more than one hundred subjects (231). Additionally, alterations in disease activity measures 
such as DAS28, VASs and HAQ might generally reflect changes that are of importance in the 
evaluation of rheumatic disease activity, but not to the vasculature. We showed that the 
DAS28 and  patients’ and physician’s assessment of global disease activity on VASs, but not 
CRP, ESR, AIx or aPWV improved significantly between infliximab infusions in patients on 
long-term infliximab therapy (paper 1). CRP evidently reflects the total atherosclerotic risk 
(232). However, recent results from studies examining the relationship between different CRP 
genotypes, which influence natural variations in circulating CRP levels, and CVD risk argue 
against a causal association between CRP and CVD (233). Similar results have also been 
reported in studies exploring the influence of CRP genotypes on aortic stiffness. Schumacher 
et al have recently demonstrated that although circulating CRP levels and aPWV were 
significantly correlated, CRP genotypes and aPWV were not (227). Thus, the observed 
associations between vascular pathology, CVD and CRP might be due to reversed causality or 
residual confounding, and not fully reflect the vascular inflammatory processes.  
Calprotectin has for several years been an accepted biomarker reflecting disease activity in 
inflammatory arthropathies (chapter 1.6). During the later years, the heterodimer has also 
been increasingly associated with CVD. Previous studies in apparently healthy 
postmenopausal women and in patients presenting with acute coronary syndromes, have 
demonstrated that elevated plasma calprotectin levels predicted cardiovascular events 
independently of traditional cardiovascular risk factors (234;235). Furthermore, the protein 
complex has been shown to be a marker of unstable plaques and an early and sensitive marker 
of myocardial necrosis in the setting of chest pain (236;237). Croce et al have recently 
reported that calprotectin promotes vascular inflammation by recruitment of neutrophils and 
increases neointimal thickening and smooth muscle proliferation in a MRP-14 knockout mice 
model (238). Many of calprotectin’s pro-inflammatory effects are probably mediated by the 
interaction with the TLR-4, which was recently identified as a receptor for calprotectin, and 
RAGE (chapter 1.6) (239;240). In the normal artery wall, TLR-4 is expressed by endothelial 
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cells, whereas in the atherosclerotic artery wall, also macrophages display TLRs. RAGE is 
expressed by macrophages, endothelial cells and smooth muscle cells. The main intracellular 
signaling pathway for both TLR-4 and RAGE includes activation of NF-κB, which leads to 
enhanced expression of pro-inflammatory cytokines (127). Thus, calprotectin might have a 
direct role in vascular pathology. We demonstrated that calprotectin was significantly 
associated with aPWV, but not to CIMT (paper 3). These findings may indicate that 
calprotectin is one determinant of aortic stiffening in inflammatory arthropathies, and a more 
sensitive measure of the vascular inflammatory processes than other inflammatory markers 
included in our studies. However, the association between calprotectin and aPWV does not 
prove causality. Although experimental results have indicated a role for calprotectin in 
inflammatory driven intima media thickening (238), data regarding the relation between 
circulating calprotectin and CIMT is limited (134). The lack of an association between 
calprotectin and CIMT in our population may reflect the relatively limited number of study 
participants (231), or the patients’ low CIMT levels. Thus, further studies are needed to 
clarify calprotectin’s role in arterial stiffening and intima media thickening.  
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6 Conclusions and clinical implications 
6.1 Conclusions 
1. Infliximab infusions did not alter aPWV or AIx in patients with inflammatory 
arthropathies who were on long-term infliximab therapy (paper 1).  
2. Anti-TNF-α therapy improved aPWV after three months, and the beneficial treatment 
effect was maintained throughout the one-year follow-up period in patients with inflammatory 
arthropathies, but did not influence AIx (paper 2 and 3). 
3. One year of anti-TNF-α therapy reduced CIMT progression in patients with 
inflammatory arthropathies (paper 3). 
4. Calprotectin was longitudinally associated with aPWV after initiation of anti-TNF-α 
therapy in patients with inflammatory arthropathies. There were no significant correlations 
between changes in aPWV, CRP and ESR. CIMT and AIx were not associated with 
inflammatory markers, neither at baseline nor longitudinally (paper 2 and 3). 
5. Disease activity assessed by VASs, HAQ and DAS 28 was not associated with aPWV, 
AIx and CIMT (paper 1, 2 and 3).  
6. Treatment with TNF-α antagonists increased plasma L-arginine and the L-
arginine/ADMA ratio but did not affect ADMA in patients with inflammatory arthropathies. 
Plasma ADMA levels and the L-arginine/ADMA ratio were cross-sectionally associated with 
aPWV, and the L-arginine/ADMA ratio was continuously associated with aPWV after 
initiation of anti-TNF-α therapy (paper 4).  
6.2 Clinical implications  
We demonstrated in this thesis a beneficial effect of anti-inflammatory therapy targeting the 
pro-inflammatory cytokine TNF-α on vascular function and structure in patients with 
inflammatory arthropathies. Patients with RA, AS and PsA are at an increased risk for CVD 
largely attributable to a chronic systemic inflammation. Our results indicate that the pro-
inflammatory protein calprotectin is associated with arterial stiffness, and might be one 
mediator of vascular pathology in patients with inflammatory arthropathies. Primary and 
secondary CVD prevention in patients with RA, AS and PsA should follow the current 
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national cardiovascular prevention guidelines (241). However, it also seems important to aim 
at controlling the inflammatory activity in these patients with regard to their CVD risk. Our 
results suggest that arterial stiffening in inflammatory arthropathies might be reversible, and 
that the beneficial effect of anti-inflammatory therapy might occur shortly after initiation of 
treatment. The favorable effect of TNF-α antagonists on CIMT progression shown in this 
thesis might imply a possible reduction in cardiovascular events due to anti-inflammatory 
therapy in RA, AS and PsA. However, results regarding long-term cardiovascular outcomes 
after anti-inflammatory treatment in inflammatory arthropathies are limited, and further 
research within this field is needed to improve cardiovascular prevention strategies in these 
patients.  
The relevance of our findings in patients with CVD but without a chronic inflammatory 
disease is uncertain. To date, anti-inflammatory treatment strategies in CVD have not been 
very successful, and anti-TNF-α therapy may worsen heart failure. However, our results 
support the view that inflammatory processes are important in vascular pathology.  
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Abstract 
Background: Anti-Tumor Necrosis Factor (TNF)-α therapy seems to improve vascular 
pathology in patients with inflammatory arthropathies such as rheumatoid arthritis, ankylosing 
spondylitis and psoriatic arthritis.  Asymmetric dimethylarginine (ADMA) competes with L-
arginine as a substrate for nitric oxide synthase (NOS) and the L-arginine/ADMA ratio is 
important for modulation of the NOS activity. We examined the effect of TNF-α antagonists 
on circulatory ADMA and L-arginine/ADMA, and associations between ADMA, L-
arginine/ADMA, aortic stiffness and carotid intima media thickness (CIMT) in patients with 
inflammatory arthropathies.  
Methods: Fifty-five patients with a clinical indication for anti-TNF-α therapy were included. 
36 patients started with anti-TNF-α therapy and were compared with a non-treated group of 
19 patients. Plasma ADMA, L-arginine and aortic stiffness (aortic pulse wave velocity, 
aPWV) were assessed at baseline, 3 and 12 months. CIMT was examined at baseline and 12 
months.   
Results: Anti-TNF-α therapy for 12 months increased the L-arginine/ADMA ratio (mean 
[SD]) in the treatment group compared to the control group (9 [30] vs. -7 [22], P=0.03), but 
did not affect ADMA (0.01 [0.09] μmol/L vs. 0.00 [0.09] μmol/L, P=0.88). Baseline aPWV 
was associated with ADMA (P=0.02) and L-arginine/ADMA (P=0.02) in multiple regression 
analyses, and the association between the L-arginine/ADMA ratio and aPWV was maintained 
after initiation of anti-TNF-α therapy (P=0.03). ADMA and L-arginine/ADMA were not 
correlated with CIMT. 
Conclusion: Anti-TNF-α therapy improved the L-arginine/ADMA ratio in patients with 
inflammatory arthropathies. ADMA and the L-arginine/ADMA ratio were associated with 
aPWV, and may have a mechanistic role in the aortic stiffening observed in these patients. 
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Introduction 
Chronic inflammatory arthropathies such as rheumatoid arthritis (RA), ankylosing spondylitis 
(AS) and psoriatic arthritis (PsA) are associated with premature aortic stiffening and 
accelerated atherosclerosis (1;2). Previous results indicate that inflammatory mechanisms are 
involved in the vascular pathology in these patients. The pro-inflammatory cytokine Tumor 
Necrosis Factor-α (TNF-α) is central in inflammatory initiation and amplification in both 
inflammatory arthropathies and atherosclerosis. We have recently reported that treatment with 
TNF-α antagonists improved aortic stiffness and carotid intima media thickness (CIMT) 
progression in patients with inflammatory arthropathies (3;4). 
Endothelium derived nitric oxide (NO) is an important vasodilatator and regulator of vascular 
homeostasis. NO is produced from the amino acid L-arginine by the enzyme nitric oxide 
synthase (NOS). Asymmetric dimethylarginine (ADMA) is an endogenous NOS inhibitor, 
which competes with L-arginine as a substrate for NOS (5). The relationship between ADMA 
and L-arginine, expressed as the L-arginine/ADMA ratio, is suggested to be important for 
modulation of NOS activity (6). Circulating ADMA levels have previously been shown to 
independently predict myocardial infarctions in the general population (7) and cardiovascular 
events in patients who had undergone percutaneous coronary intervention (8). Recent reports 
indicate that patients with inflammatory arthropathies have increased plasma levels of ADMA 
compared to both healthy controls and patients with osteoarthritis (9-14).  TNF-α has 
previously been demonstrated to increase ADMA levels in cell culture studies (15;16). Thus, 
increased ADMA and/or reduced L-arginine/ADMA ratio may contribute to the vascular 
pathology seen in inflammatory arthropathies, and anti-TNF-α therapy might be beneficial in 
this aspect.  
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The objectives of the present study were to explore the effect of anti-TNF-α therapy on 
plasma ADMA levels and the L-arginine/ADMA ratio in patients with inflammatory 
arthropathies, and to examine associations between ADMA, the L-arginine/ADMA ratio and 
aortic stiffness and CIMT.  
 
Methods 
Design and patients  
Sixty patients with RA, AS or PsA were recruited from two major rheumatology outpatient 
clinics in the Oslo area to a prospective, non randomized study as reported in detail previously 
(3;4). In brief, inclusion criteria were an active inflammatory disease and a clinical indication 
for anti-TNF-α therapy. Exclusion criteria for the present analyses were uncontrolled arterial 
hypertension (systolic pressure ≥ 140 mmHg and/or diastolic pressure ≥ 90 mmHg), reduced 
kidney function (serum creatinine > 133 mmol/L for men and > 124 mmol/L for women) and 
diabetes mellitus (fasting plasma glucose ≥ 7.0 mmol/L or current use of anti-diabetic 
medication). Patients with changes in anti-hypertensive or lipid-lowering medication, or 
patients who initiated treatment with other biological disease-modifying anti-rheumatic 
therapy such as treatment targeting B-cells (rituximab), T-cells (abatacept), IL-1 (anakinra) or 
IL -6 (tocilizumab) during the study period would be excluded.  
The present study included vascular measurements and fasting blood samples from the 
baseline (immediately before a possible start with a TNF-α antagonist), three and 12 months 
examinations. CIMT was measured at baseline and at 12 months. Five patients ended therapy 
during the follow-up period due to treatment failure, allergic reactions or suspected cancer, 
and were excluded from the analyses. Thirty-six patients continued anti-TNF-α treatment for 
one year (17 with etanercept, 10 with adalimumab, and 9 with infliximab), and these patients 
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were compared to a control group of 19 patients who remained without anti-TNF-α treatment 
during the total follow-up period. Reasons to postpone therapy initiation were positive 
Mantoux’ test, planned operations, fear of side effects, or co- morbidities. Approval was 
obtained from the regional research ethics committee, and written informed consent was 
obtained from each participant. The study was performed according to the Helsinki-
declaration. 
 
Vascular measurements 
Patients were examined in a quiet, temperature-controlled room after an overnight fast. All 
examinations were performed with the patients in a supine position after a minimum of 10 
minutes relaxation. Systolic and diastolic brachial blood pressures were measured with an 
appropriately sized cuff using a validated automated device (Omron HEM-757, Kyoto, 
Japan).  
Aortic stiffness, central hemodynamic measures and the augmentation index (AIx) were 
assessed with the Sphygmocor device version 7.1 (AtCor Medical, Sydney, Australia) and a 
validated tonometer (SPC-301; Millar instruments, Houston, USA) as previously reported (4). 
Aortic stiffness was assessed as carotid-femoral pulse wave velocity, which is considered to 
give an estimate of aortic pulse wave velocity (aPWV). The wave travel distance was 
obtained by subtracting the distance from the carotid location to the sternal notch from the 
distance between the sternal notch and the femoral site of recording. Mean arterial pressure 
(MAP) was determined from the pressure waveforms obtained at the radial artery calibrated 
with brachial blood pressures. 
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CIMT was measured in the common carotid artery (CCA) using the multiarray echotracking 
system Art.Lab (Esaote, Maastricht, the Netherlands) equipped with a 10-5 MHz linear array 
transducer as previously reported (3). The system utilizes rough radio frequency data to 
automatically register IMT of the CCA for each subsequent cardiac cycle over a period of 6 
seconds (17). Measurements were performed in the far wall of approximately 2 cm long 
segments in the distal CCA close to the carotid bulb on both sides. CIMT measurements in 
two patients were excluded from analyses because of insufficient quality. 
All vascular and blood pressure measurements were made in triplicate by the same examiner 
(KA), and their mean was used in the analyses. The repeatability for the vascular 
measurements are previously reported (3). The examiner did not participate in the treatment 
of the rheumatic disorder, and information of the patients’ treatment was disclosed after 
completion of data collection and analyses. 
 
Laboratory measurements 
Erythrocyte sedimentation rate (ESR), total cholesterol (TC), low density lipoprotein 
cholesterol (LDL), high density lipoprotein cholesterol (HDL), triglycerides (TG), creatinine 
and C-reactive protein (CRP) were determined by routine methodology at the time of 
examinations. EDTA plasma samples were stored at −80°C until analyzed for L-arginine and 
ADMA, determined by high performance liquid chromatography (HPLC) and precolumn 
derivatization with o-phthaldialdehyde (OPA) (Sigma Chemicals Co, St.Louis, MO) as 
previously described (18). The inter-assay CV were < 5% for both.  
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Statistical analyses 
Continuous data are presented as mean with standard deviation or as geometric mean with 
95% confidence interval in skewed variables. Comparison of continuous data was done with 
Student’s independent sample test, using log-transformed values in the case of skewed 
variables. Categorical variables are expressed as numbers and were compared with Pearson’s 
χ² test. Baseline associations with aPWV and CIMT as dependent variables were examined 
with multiple linear regression analyses. Associations between the vascular parameters and 
ADMA or L-arginine/ADMA adjusted for anti-TNF-α therapy over time were explored using 
multivariable mixed linear regression models, which included the interaction between time 
and anti-TNF-α therapy. We used an unstructured covariance structure in the mixed model 
analyses. Mixed model repeated measures analysis is a linear regression analysis that controls 
for multiple testing of the same patient by modeling the covariance between the repeated 
measurements of each individual as a clustered random effect. Variables that were associated 
(P-value < 0.25) with the vascular measurements in bivariate analyses, or variables known to 
influence these measurements, were entered into the linear regression and mixed models and 
subsequently removed in a step-down manner according to levels of significance. Because 
ADMA is correlated with kidney function and body weight, all regression analyses were 
adjusted for creatinine and body mass index (BMI). The models were examined for relevant 
interactions and confounding in a standard manner. P-values ≤ 0.05 were considered 
significant. Statistical analyses were performed with SPSS, version 18.0 (SPSS Inc., Chicago, 
USA) and R (R Development Core Team, 2008. R Foundation for Statistical Computing, 
Vienna, Austria). 
 
Results 
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Patients’ demographic, baseline biochemical and hemodynamic parameters did not differ 
between the anti-TNF-α group and the control group (Table 1). Geometric means were 
preferred to median values due to the use of non-transformed values in the regression 
analyses.  
Changes in L-arginine, ADMA and L-arginine/ADMA in the two patients groups from 
baseline to 3 and 12 months, respectively, are presented in Table 2. These values were 
normally distributed, and are therefore presented as mean with standard deviation. L-arginine 
and L-arginine/ADMA levels were significantly improved in the gropu receiving anti-TNF-α 
therapy compared to the control group different in the two patients groups both at the 3 and 12 
months visits. ADMA plasma levels did not change in any of the two groups during the 
follow-up period.  
The final multiple linear regression analyses with baseline aPWV as dependent variable are 
presented in Table 3 a) and b). Baseline aPWV was significantly associated with both ADMA 
(P=0.02) and the L-arginine/ADMA ratio (P=0.02). L-arginine was not associated with 
baseline aPWV. Separate models with ADMA and L-arginine/ADMA as independent 
variables are presented due to the high co-linearity between these variables. Non-transformed 
or log-transformed values of ADMA and L-arginine/ADMA gave similar results, and the 
results from the analyses with the non-transformed values are presented. The validity of the 
models was confirmed by the normal distribution of the residuals. Neither L-arginine, ADMA 
nor the L-arginine/ADMA ratio was associated with AIx, central blood pressures or CIMT 
(data not shown).   
In the multivariable mixed regression analyses, which included the variable anti-TNF-α 
therapy over time, the L-arginine/ADMA ratio was associated with aPWV (Table 4), whereas 
L-arginine and ADMA were not (data not shown). L-arginine, ADMA and L-arginine/ADMA 
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were neither associated with AIx, central blood pressures nor CIMT (data not shown).  Log-
transformed values of ADMA, L-arginine or L-arginine/ADMA gave similar results.  
The diagnose of inflammatory arthropathy, comorbidities, HR, use of anti rheumatic therapy 
besides TNF-α antagonists, or biochemical variables such as CRP, ESR, creatinine, TC, LDL, 
HDL and TG were not associated with aPWV in any of the regression models (data not 
shown). All regression models were adjusted for creatinine and BMI. 
  
Discussion 
The present study examined the effect of treatment with TNF-α antagonists on plasma 
ADMA, L-arginine and L-arginine/ADMA levels in patients with inflammatory arthropathies. 
The patients receiving anti-TNF-α therapy showed improved L-arginine/ADMA ratio 
compared to the patients in the control group, but anti-TNF-α therapy did not affect ADMA 
levels. Plasma ADMA levels and the L-arginine/ADMA ratio were associated with aPWV, 
and the L-arginine/ADMA ratio was longitudinally related to aPWV after initiation of anti-
TNF-α therapy.  
Vascular pathology is considered to be associated with the inflammatory activity in patients 
with RA, AS and PsA (1;2). Unfavourable changes in the L-arginine/ADMA ratio driven by 
inflammatory processes might be one part of the explanation for this association. 
Inflammatory markers such as CRP and IL-6 have been demonstrated to correlate with 
reduced circulatory L-arginine and L-arginine/ADMA ratio and increased ADMA in several 
patient populations (10;11;13;14;19) as well as in the general population (14;19;20). 
Furthermore, Antoniades et al have recently reported that systemic low grade inflammation 
after Salmonella typhii vaccination increased serum ADMA levels and concordantly reduced 
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FMD in healthy individuals (14). Several previous studies have shown a beneficial effect of 
anti-inflammatory treatment on vascular pathology in patients with inflammatory 
arthropathies (1;3;4;21). However, the effects of such therapy on plasma ADMA levels and 
the L-arginine/ADMA ratio have to our knowledge not previously been examined in 
longitudinal studies. The observed favourable effect of anti-TNF-α therapy on the L-
arginine/ADMA ratio in the present study was related to a change in L-arginine levels but not 
in ADMA levels. Inflammatory processes have been suggested to decrease L-arginine levels 
and consequently the L-arginine/ADMA ratio by increasing the activity of arginase, an 
enzyme that converts L-arginine into L-ornithine, and by reduction of L-arginine transport 
into endothelial cells by the y+-transporter system (22). Somewhat surprising, we could not 
find any effect of anti-TNF-α therapy on ADMA levels in our population. TNF-α has 
previously been demonstrated to increase the ADMA concentration in human endothelial cells 
in vitro by reducing the activity of the enzyme dimethylarginine dimethyl-aminohydrolase 
(DDAH) (16). DDAH is the main catabolic pathway for ADMA, and the activity of DDAH 
strongly affects plasma ADMA levels (23). However, two previous cross sectional studies in 
patients with AS have reported that serum ADMA levels in patients exposed to a TNF-α 
antagonist were equal to the levels in conventionally treated patients (9;10), and previous 
intervention studies with statins and antagonists of the renin-angiotensin system have revealed 
inconsistent results with regard to the effect of medical intervention on circulatory ADMA 
levels (24). These results may indicate that a reduction in ADMA is difficult to demonstrate. 
Furthermore, the baseline ADMA levels in our population were compared to previous reports 
in the normal range, whereas the L-arginine/ADMA ratio was in the lower range (Table 1) 
(6). Thus, the potential for a reduction in ADMA might have been limited in our population.   
AIx and aPWV are both influenced by endothelial function, and have previously been 
demonstrated to increase after administration of ADMA or another endogenous NOS 
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inhibitor, N-monomethylarginine (L-NMMA) (25-27). ADMA inhibition of NO synthesis 
may reduce the NO mediated smooth muscle relaxation and thus the arteries’ capacity of 
vasodilatation (28). In our population, ADMA and the L-arginine/ADMA ratio were 
independently associated with baseline aPWV independent of related covariates (Table 3). 
These findings correspond with a previous report of an inverse correlation between ADMA 
levels and coronary flow reserve in patients with RA (12). On the other hand, Kemeny-Beke 
et al have recently reported that FMD in the brachial artery and serum ADMA levels in 
patients with AS were not correlated (9). However, in the latter study, approximately half of 
the patients were on treatment with a TNF-α antagonist. Anti-TNF-α therapy has previously 
been demonstrated to improve FMD (1;21), and treatment with TNF-α antagonists may have 
influenced a possible correlation between FMD and ADMA. We have previously reported 
that improvement in aortic stiffness after initiation of treatment with TNF-α antagonist 
predominantly occurred during the first three months of therapy (3). In the present study, the 
main change in the L-arginine/ADMA ratio also took place in the same period (Table 2), and 
the L-arginine/ADMA ratio was associated with aPWV in the multivariable analysis which 
included the interaction variable anti-TNF-α therapy x time (Table 4). Thus, improvement in 
the L-arginine/ADMA ratio may have contributed to the observed improvement in aPWV 
during anti-TNF-α therapy. We could not demonstrate any correlation between central 
pressures or AIx and ADMA or the L-arginine/ADMA ratio. These negative findings may be 
due to lack of power, but previous results have indicated that aortic stiffness might be a better 
measure of arterial stiffening than AIx in patients with inflammatory arthropathies (1;3;4). 
This difference in sensitivity might be due to the peripheral vasodilatation associated with 
systemic inflammation, which would counteract the effect of the inflammation induced aortic 
stiffening on pulse wave reflections and the AIx.    
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Previous studies indicate that circulating ADMA levels are associated with CIMT (20;29)  
and predict CIMT progression (29) in the general population, although a large cross sectional 
study in a Framingham heart study offspring cohort found significant association only to 
internal carotid artery or carotid bulb IMT and not to CIMT (30). Data regarding the 
correlation between ADMA and CIMT in patients with inflammatory arthropathies are to date 
inconsistent (9;11;12), and we did not observe any association between CIMT and ADMA, L-
arginine or the L-arginine/ADMA ratio. However, the patients in the present study had CIMT 
values within the normal range (Table 1), and correlations between ADMA, L-arginine and 
CIMT may be easier to judge in higher age groups with more pronounced atherosclerosis or in 
larger patients groups.  
The present study has some limitations. The patients were not randomized to treatment or 
placebo due to ethical reasons. The non-randomized design could have introduced potential 
bias. However, the treatment and control groups were recruited from the same clinical setting 
and the two patient groups did not differ with regard to demographic characteristics or 
baseline inflammatory and hemodynamic measures. In our previous reports from the same 
patient population, repeated analyses after matching the patients by age, sex and MAP did not 
change the results (4). Furthermore, the associations between aPWV and ADMA and the L-
arginine/ADMA ratio in the present study are not proven to be causal, and need further 
exploration in future studies.  
In conclusion, initiation of anti-TNF-α therapy improved the plasma L-arginine/ADMA ratio, 
but did not influence plasma ADMA levels in patients with inflammatory arthropathies. 
Plasma ADMA levels and the L-arginine/ADMA ratio were associated with baseline aPWV, 
and the L-arginine/ADMA ratio was furthermore longitudinally associated with aPWV after 
initiation of anti-TNF-α therapy. These findings indicate that ADMA and L-arginine/ADMA 
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may have a mechanistic role in the aortic stiffening seen in patients with inflammatory 
arthropathies. 
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Table 1. Patients’ demographic and baseline biochemical and hemodynamic parameters 
 Anti-TNF-α 
(n=36) 
Control 
(n=19) 
 
P 
Demographic    
Patient age, yrs 47.2 (11.6) 51.9 (14.5) 0.16 
Females / males, n  14 / 22 8 / 11 0.82 
Disease duration, yrs 10.1 (8.8) 11.9 (11.3) 0.50 
RA / AS / PsA, n 15 / 12 / 9 10 / 7 / 2 0.43 
BMI, kg/m2 26.0 (6.7) 26.0 (3.1) 0.94 
Biochemical 
L-arginine, μmol/L 78 [74, 82] 78 [71, 86] 0.86 
ADMA, μmol/L 0.59 [0.54, 0.65] 0.58 [0.50, 0.68] 0.83 
L-arginine/ADMA, ratio 132 [119, 145] 136 [117, 156]  0.75 
Creatinine, μmol/L 67.9 [63.2, 72.5] 72.2 [66.0, 79.0] 0.17 
CRP, mg/ L 5.6 [3.2, 8.8] 5.4 [3.0, 9.6] 0.88 
ESR, mm/h 13.0 [9.9, 17.2] 12.7 [7.1-22] 0.95 
Hemodynamic 
aPWV, m/s 7.48 (1.60) 7.50 (1.00) 0.95 
CIMT, mm* 0.560 (0.112) 0.563 (0.110) 0.95 
Brachial SBP, mm Hg 131 (19) 131 (22) 0.99 
Brachial DBP, mm Hg 79 (11) 78 (11) 0.69 
Central SBP, mm Hg 120 (19) 123 (21) 0.68 
Central PP, mm Hg 40 (11) 44 (13) 0.22 
MAP, mm Hg 98 (14) 97 (14) 0.88 
HR, bpm 64 (9) 62 (10) 0.46 
AIx, % 20.0 (12.1) 22.9 (10.8) 0.38 
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SBP indicates systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; HR, 
heart rate; *n=34 in the Anti-TNF-α group. Values are represented as mean (SD) or numbers, 
except for ADMA, L-arginine, L-arginine/ADMA, creatinine, CRP and ESR which were 
skewed and are represented as geometric mean [95% confidence interval]. 
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 Table 2. Changes from baseline in L-arginine, ADMA and the L-arginine/ADMA ratio 
 3 months  12 months 
 Anti-TNF-α  
(n=36) 
Control 
(n=19) 
 
P 
 Anti-TNF-α 
(n=36) 
Control 
(n=19) 
 
P 
L-arginine, μmol/L 6 (17) -3 (10) 0.03  6 (10) -1 (14) 0.03 
ADMA, μmol/L 0.01 (0.10) 0.02 (0.07)  0.72  0.01 (0.09) 0.00 (0.09) 0.88 
L-arginine/ADMA 10 (35) -13 (20) 0.01  9 (30) -7 (22) 0.03 
Values are given as mean (SD). P values refer to between group comparisons of changes after 
3 and 12 months, respectively. 
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Table 3 a) and b). Multiple linear regression analyses for baseline associations with aPWV 
  
Regression Coefficient (95% CI) 
 
P  
Male sex 0.31 (-0.26, 0.87) 0.41 
Age, years 0.07 (0.04, 0.09) <0.001 
MAP, mmHg 0.03 (0.01, 0.06) 0.003 
ADMA, μmol/L 1.70 (0.27, 3.35) 0.02 
  
  
Regression Coefficient (95% CI) 
 
P  
Male Sex 0.32 (-0.16, 1.03) 0.15 
Age, years 0.07 (0.04, 0.09) <0.001 
MAP, mmHg 0.03 (0.08, 0.055) 0.01 
L-arginine/ADMA -0.01 (-0.02, -0.00) 0.02 
CI indicates confidence interval. 
 
 
a) 
b) 
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Table 4.  Multivariable mixed model with aPWV as dependent variable (n=55, 3 visits) 
  
Regression Coefficient (95% CI) 
 
P 
Male sex 0.17 (-0.39, 0.72) 0.55 
Age, years 0.07 (0.05, 0.09) <0.001 
Anti-TNF-α therapy 0.42 (-0.15, 1.00) 0.15 
Time -0.03 (-0.05, -0.01) 0.004 
Anti-TNF-α therapy × Time -0.04 (-0.07, -0.01) 0.02 
MAP, mmHg 0.02 (0.01, 0.03) <0.001 
L-arginine/ADMA  -0.004 (-0.007, -0.000) 0.03 
CI indicates confidence interval; Anti-TNF-α therapy × Time, treatment (yes/no) multiplied 
with months after baseline.  
 
 
 
 
 
 
 
 
 
 
 
 
